Drs Peter Martin and Kami Maddocks discuss bendamustine, its effectiveness in older patients, and the challenge of combining treatments or other medications with that backbone.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982890). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Mantle Cell Lymphoma https://emedicine.medscape.com/article/203085-overview

Bendamustine https://reference.medscape.com/drug/bendeka-belrapzo-bendamustine-342133

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment for Patients With Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised, Phase 3 Non-Inferiority Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61763-2/fulltext

Randomized Trial of Bendamustine-Rituximab or R-CHOP/R-CVP in First-Line Treatment of Indolent NHL or MCL: The BRIGHT Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260975/

ECOG-ACRIN E1411 Randomized Phase 2 Trial of Bendamustine-Rituximab (BR)-Based Induction Followed by Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma: Effect of Adding Bortezomib to Front-Line BR Induction on PFS. https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.7503

A Phase 1/1b Study of Rituximab, Bendamustine, and Ibrutinib in Patients With Untreated and Relapsed/Refractory Non-Hodgkin Lymphoma https://ashpublications.org/blood/article/125/2/242/34217/A-phase-1-1b-study-of-rituximab-bendamustine-and

Ibrutinib Plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35657079/

Five-Year Outcomes of the S1106 Study of R-Hyper-CVAD vs R-Bendamustine in Transplant-Eligible Patients With Mantle Cell Lymphoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849956/

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab, and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 Years Old With Untreated Mantle Cell Lymphoma https://ecog-acrin.org/clinical-trials/ea4181-educational-materials/

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission https://ecog-acrin.org/clinical-trials/ea4151-mantle-cell-lymphoma/

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts https://pubmed.ncbi.nlm.nih.gov/35763708/

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study https://pubmed.ncbi.nlm.nih.gov/35658525/

Efficacy and Safety of Ibrutinib Combined With Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients With Mantle Cell Lymphoma: Results From the Randomized Triangle Trial by the European MCL Network https://ash.confex.com/ash/2022/webprogram/Paper163018.html